Pharmafile Logo
Pharmafocus logo
Advanced Search

DME

Showing 5 posts of 5 posts found.

Novartis eye treatment for diabetics shows positive results in Phase III trial

May 4, 2021
Manufacturing and Production DME, Novartis, diabetic macular edema, macular edema, pharma, pharma news

Novartis’ Beovu treatment for diabetic macular edema (DME) – an eye condition that can cause blindness – has shown positive …

News
Roche image

FDA clears Roche eye drug

February 9, 2015
Sales and Marketing AMD, DME, FDA, Lucentis, Retina, Roche, eyes, ranibizumab

The US Food and Drug Administration has shown Roche’s eye-condition drug Lucentis the green light to treat patients with diabetic …

News
Eylea image

Bayer submits Eylea in EU for DME

November 8, 2013
Sales and Marketing Bayer, DME, EMA, Eylea, FDA

Bayer HealthCare is seeking to extend the licence of its VEGF Trap-Eye, which is already marketed as Eylea in various …

News
Eylea image

Eylea trial boost in DME

August 7, 2013
Research and Development, Sales and Marketing Bayer, DME, Eylea, regenenron

The rival treatment to Novartis’ Lucentis has posted encouraging new study results in patients with diabetic macular oedema (DME). In …

News

Lucentis boosted by diabetic vision study

May 24, 2010
Research and Development, Sales and Marketing AMD, DME, Lucentis, Novartis

A phase III trial of Novartis’ ranibizumab has shown it to be superior at promoting vision gain in patients with …

News

Latest content

Shionogi and Maze Therapeutics announce worldwide exclusive licensing agreement for novel Pompe disease candidate

May 10, 2024

Sanofi and Novavex sign exclusive $1.2bn licensing agreement to co-commercialise COVID-19 vaccine and develop flu-COVID-19 vaccines

May 10, 2024

AstraZeneca withdraws COVID-19 vaccine Vaxzevria

May 9, 2024

Nxera Pharma partner Neurocrine Biosciences enters phase 1 NBI-1117567 study

May 9, 2024

Mirum Pharmaceuticals publishes phase 3 MARCH maralixibat data in The Lancet

May 8, 2024